Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Multiple Cancer Types

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Lung, Small Cell
III
Iams, Wade
NCT03703297
VICCTHO1901

Molecular Predictors of Lung Cancer Behavior. (SPORE)

Multiple Cancer Types

Lung, Non Small Cell, Small Cell
N/A
Massion, Pierre
NCT00898313
VICCTHO0398

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: